Synapse - Advanced Practice Providers

Results (179)

Feasibility, tolerability, and patient-reported outcomes with pharmacokinetic (PK)-directed dosing of Evomela (propylene glycol free melphalan) for multiple myeloma and AL amyloidosis patients undergoing autologous hematopoietic stem cell transplant (AHCT)

Meeting Abstract

Shah, G. L.; Lin, A.; Schofield, R.; Sarubbi, C.; Preston, E. V.; Devlin, S. M.; Bhatt, V.; Harnicar, S. J.; Hoover, E.; Chung, D. J.; more...
Blood (2017)

Fulltext@MSK | Save

A phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory B-and T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M. A.; Lynch, P.; Scheuerman, M.; Minnal, V.; Galasso, N.; Kumar, A.; Gerecitano, J.; Zelenetz, A. D.; more...
Blood (2017)

Fulltext@MSK | Save

Vaccines are safe and effective after T-cell depleted CD34-selected allogeneic hematopoietic stem cell transplantation (Allo HCT)

Meeting Abstract

Malard, F.; Shah, G. L.; Seier, K.; Cho, C.; Devlin, S. M.; Maloy, M.; Borrill, T.; Palazzo, M.; van den Brink, M.; Perales, M. A.
Bone Marrow Transplantation (2017)

Fulltext@MSK | Save

Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma

Journal Article

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
Blood (2017)

Fulltext@MSK | Save

A Phase I study of ibrutinib combined with rituximab, ifosfamide, carboplatin, and etoposide in patients with relapsed or primary diffuse large B-cell lymphoma

Meeting Abstract

Sauter, C. S.; Matasar, M. J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
Hematological Oncology (2017)

Fulltext@MSK | Save

Prospective evaluation of unrelated donor cord blood and haploidentical donor access reveals graft availability varies by patient ancestry: Practical implications for donor selection

Journal Article

Kosuri, S.; Wolff, T.; Devlin, S. M.; Byam, C.; Mazis, C. M.; Naputo, K.; Davis, E.; Paulson, J.; Nhaissi, M.; Wells, D. S.; more...
Biology of Blood and Marrow Transplantation (2017)

Fulltext@MSK | Save

Re-immunization following autologous hematopoietic stem cell transplantation (Auto HCT) is safe and effective in patients with multiple myeloma receiving lenalidomide maintenance

Meeting Abstract

Shah, G.; Palazzo, M.; Copelan, O.; Seier, K.; Devlin, S.; Hassoun, H.; Korde, N.; Lendvai, N.; Lesokhin, A.; Mailankody, S.; more...
Clinical Lymphoma, Myeloma and Leukemia (2017)

Fulltext@MSK | Save

A Phase Ib/IIa trial of the combination of romidepsin, lenalidomide and carfilzomib in patients with relapsed/refractory lymphoma shows complete responses in relapsed and refractory T-cell lymphomas

Meeting Abstract

Mehta-Shah, N.; Moskowitz, A. J.; Lunning, M.; Lynch, P.; Scheuerman, M.; Kumar, A.; Gerecitano, J. F.; Zelenetz, A. D.; Hamlin, P. A. Jr; Noy, A.; more...
Blood (2016)

Fulltext@MSK | Save

PET-adapted therapy with brentuximab vedotin and augmented ICE for relapsed/refractory Hodgkin lymphoma - Lack of Improvement with 3 versus 2 cycles of weekly brentuximab vedotin

Meeting Abstract

Moskowitz, A. J.; Schöder, H.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; Hamlin, P. A.; Horwitz, S.; Kobos, R.; more...
Haematologica (2016)

Fulltext@MSK | Save